HIV InfectionOBSOCAMNCT06913959
HIV-1 Non-group M in Cameroon : Study of Genotypic and Phylogenetic Diversity (OBSOCAM)
An observational study of HIV Infection, run by ANRS, Emerging Infectious Diseases.
Trial summary
The aim of the study is to study the genotypic characteristics of HIV-1 non-M circulating in the whole Cameroon and their genetic evolution. Read more about this study
- Who is it for?
- Ages 21 years and older
- Conditions the study is for
- HIV Infection
- What is being tested?
- Prospective
- How many people
- 220 participants
- Where
- No sites listed yet
- Study dates
- Dec 2026to 1 Jul 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Retrospective phase : Dried Blood Spot samples tested positive for HIV during the Demographic health surveys in Cameroon 2011 and 2018 surveys, serotyping for HIV. Prospective phase : Individuals who came to Center Pasteur Cameroon in Yaoundé or Garoua for HIV screening or viral load monitoring, serotyping of HIV for positive samples.
Who may be able to join
- All available samples tested positive for HIV during the national Health survey of Cameroon in 2011 And 2018
- All Individuals who came to Centre Pasteur in Yaoundé or Garoua for HIV screening or viral load monitoring.
Who cannot join
- Insufficient quantity or degraded Dried Blood Spot samples
- All HIV-positive individuals aged less than 21 years, infected with a Group M HIV-1 virus, or those who refused to participate in the study
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
The aim of the study is to study the genotypic characteristics of HIV-1 non-M circulating in the whole Cameroon and their genetic evolution.
Read the detailed description
HIV-1 is divided four distinct groups: M (major) which represents the pandemic strains while others groups O (outlier), N (non M, non O) and P are called non-M variants. Group O (HIV-O) is more divergent, endemic in Central Africa and Cameroon, where it represents about 1% of HIV infections. These variants are characterized by an important genetic divergence from pandemic HIV-1 group M (HIV-M), which impacts on the diagnosis, monitoring and treatment of infected patients. Although discovered in 1990, and emerged at the same time as HIV-M, no data of epidemiology, natural history and evolution of the genetic diversity of these variants is currently available. The few knowledge available to date come from sporadic cases, mainly through studies in Yaoundé. It is therefore essential to improve current knowledge on these variants and their consequences on infected patients.
The aim of the study is to study the genotypic characteristics of HIV-1 non-M circulating in the whole Cameroon and their genetic evolution.
- Conditions
- HIV Infection
- Being tested
- Prospective
- Keywords
- HIV genetic diversity, HIV-1 non-M variants
- Medical subject headings
- HIV Infections
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ProspectiveDiagnostic test
Blood samples will be collected in order to meet the objectives of this substudy and possibly for complementary research
| Study group | Role | What they receive |
|---|---|---|
| Retrospective | Dried Blood Spot samples tested positive for HIV during the previous national epidemiologic surveys Demographic health surveys in Cameroon Receives: Diagnostic Test: Prospective | |
| Prospective | Individuals who came to Center Pasteur in Yaounde or Garoua for HIV screening or viral load monitoring Receives: Diagnostic Test: Prospective |
What is being measured
The primary outcome is the main question the study is designed to answer.
Prevalence of non-M HIV-1 in Cameroon
Number of participants infected with non-M HIV-1 included compared to the total expected number of inclusions
Measured: 1 day
Secondary outcomes (1)
Investigate the current molecular epidemiology of resistance in non-M HIV-1 variants in Cameroon
Proportion of non-M HIV-1 samples characterized genotypically among the samples collected from participants included in the project
Measured: 1 Day
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Apr 2025
- Study startDec 2026 (estimated)
- Primary completion1 Jul 2027 (estimated)
- Study completion1 Jul 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HIV InfectionStudies of the same condition, open and under way.
- More trials run by ANRS, Emerging Infectious DiseasesThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 220 participants (estimated)
Sponsor and investigators
- Lead sponsor
- ANRS, Emerging Infectious Diseases
- Sponsor type
- Other government
- Collaborators
- University Hospital, Rouen, Centre Pasteur du Cameroun
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06913959
- Sponsor's protocol ID
- ANRS0098s
- Acronym
- OBSOCAM
- Status last verified
- Oct 2026
- First submitted
- 31 Mar 2025
- Last updated
- 29 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 29 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- HIV-1 Non-group M in Cameroon : Study of Genotypic and Phylogenetic Diversity (OBSOCAM)
- ClinicalTrials.gov ID
- NCT06913959
- Acronym / sponsor ID
- OBSOCAM / ANRS0098s
- Conditions
- HIV Infection
- Keywords
- HIV genetic diversity, HIV-1 non-M variants
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 220 participants (estimated)
- Lead sponsor
- ANRS, Emerging Infectious DiseasesOther government
- Collaborators
- University Hospital, Rouen, Centre Pasteur du Cameroun
- Study start
- Dec 2026 (estimated)
- Primary completion
- 1 Jul 2027 (estimated)
- Study completion
- 1 Jul 2027 (estimated)
- First posted
- 6 Apr 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of the study is to study the genotypic characteristics of HIV-1 non-M circulating in the whole Cameroon and their genetic evolution.
Detailed description
HIV-1 is divided four distinct groups: M (major) which represents the pandemic strains while others groups O (outlier), N (non M, non O) and P are called non-M variants. Group O (HIV-O) is more divergent, endemic in Central Africa and Cameroon, where it represents about 1% of HIV infections. These variants are characterized by an important genetic divergence from pandemic HIV-1 group M (HIV-M), which impacts on the diagnosis, monitoring and treatment of infected patients. Although discovered in 1990, and emerged at the same time as HIV-M, no data of epidemiology, natural history and evolution of the genetic diversity of these variants is currently available. The few knowledge available to date come from sporadic cases, mainly through studies in Yaoundé. It is therefore essential to improve current knowledge on these variants and their consequences on infected patients.
The aim of the study is to study the genotypic characteristics of HIV-1 non-M circulating in the whole Cameroon and their genetic evolution.
Study design
- Observational model
- Cohort
- Time perspective
- Other
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Retrospective | – | Diagnostic Test: ProspectiveDried Blood Spot samples tested positive for HIV during the previous national epidemiologic surveys Demographic health surveys in Cameroon |
| Prospective | – | Diagnostic Test: ProspectiveIndividuals who came to Center Pasteur in Yaounde or Garoua for HIV screening or viral load monitoring |
Who may qualify
- Ages
- 21 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Retrospective phase : Dried Blood Spot samples tested positive for HIV during the Demographic health surveys in Cameroon 2011 and 2018 surveys, serotyping for HIV. Prospective phase : Individuals who came to Center Pasteur Cameroon in Yaoundé or Garoua for HIV screening or viral load monitoring, serotyping of HIV for positive samples.
Key inclusion criteria (2 listed)
- All available samples tested positive for HIV during the national Health survey of Cameroon in 2011 And 2018
- All Individuals who came to Centre Pasteur in Yaoundé or Garoua for HIV screening or viral load monitoring.
Key exclusion criteria (2 listed)
- Insufficient quantity or degraded Dried Blood Spot samples
- All HIV-positive individuals aged less than 21 years, infected with a Group M HIV-1 virus, or those who refused to participate in the study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ProspectiveBlood samples will be collected in order to meet the objectives of this substudy and possibly for complementary research | Diagnostic test | Prospective, Retrospective |
Primary outcome
Prevalence of non-M HIV-1 in Cameroon
Time frame: 1 day
Number of participants infected with non-M HIV-1 included compared to the total expected number of inclusions
1 secondary outcome
Investigate the current molecular epidemiology of resistance in non-M HIV-1 variants in Cameroon
Time frame: 1 Day
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for HIV Infection
Not yet recruiting
HealthMpowerment Korea: Pilot Testing the Cultural Adaptation of a Digital HIV Intervention for Men Who Have Sex With Men in South Korea
HIV Infections, HIV Prevention and Care
Not yet recruiting
Prescribe to Prevent HIV: A Hybrid Trial Helping Addiction Clinics Prevent HIV & Infections Through Safer Drug Use Support
People Who Use Opioids/People With Opioid Use Disorder (OUD)
Recruiting
Evaluating the Impact of Using the B-OK Bottles for HIV and ART Literacy in South Africa
HIV, HIV Treatment
Recruiting
Trial Phase: Syndemic Adapted Medly Uganda
Mental Health
RecruitingObservational study
Olfactory Function and Model-Based Behavior in People Living With HIV and SUD
HIV, Substance Use Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
An observational study of HIV Infection, run by ANRS, Emerging Infectious Diseases.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 29 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Mariam Gharib, PhD (0144236442, mariam.gharib@inserm.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Prevalence of non-M HIV-1 in Cameroon (time frame: 1 day). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Oct 2026.